# Myocarditis

*Source: [Pathway.md - Myocarditis](https://www.pathway.md/diseases/myocarditis-recnShGrKD6Fl8E3H)*


## Guidelines

### Key Sources
The following summarized guidelines for the evaluation and management of myocarditis are prepared by our editorial team based on guidelines from:
- European Society of Cardiology (ESC 2023, 2022, 2013)
- Japanese Circulation Society (JCS 2023)
- European Society of Cardiology (ESC/ESTRO/EHA/IC-OS 2022)
- American Heart Association (AHA 2020, 2016)
- European Society of Medical Oncology (ESMO 2020)

## Clinical Findings

### Symptoms
- Abdominal pain
- Arthralgia
- Chest pain
- Chills
- Diarrhea
- Dyspnea
- Exercise intolerance
- Fatigue
- Fever
- Flu-like symptoms
- Loss of appetite
- Malaise
- Myalgia
- Nausea
- Orthopnea
- Palpitations
- Skin rash
- Vomiting

### Social History
- Alcohol consumption
- Cocaine use

### Past Medical History
- Cardiac sarcoidosis
- Eosinophilic granulomatosis with polyangiitis
- Exposure to chemotherapy
- Granulomatosis with polyangiitis
- Heart failure (HF)
- Kawasaki disease
- Polyarteritis nodosa
- Radiation therapy
- Rheumatoid arthritis
- Systemic lupus erythematosus (SLE)
- Upper respiratory tract infection

## Screening and Diagnosis

### Diagnosis
As per JCS 2023 guidelines, Suspect myocarditis in patients having common cold-like symptoms (respiratory symptoms, gastrointestinal symptoms) followed by signs and symptoms associated with HF or arrhythmias. (B)

As per CCS 2017 guidelines, Suspect myocarditis in the following clinical scenarios:
- Cardiogenic shock due to LV systolic dysfunction (global or regional) with no apparent etiology
- Acute or subacute development of LV systolic dysfunction (global or regional) with no apparent etiology
- Evidence of myocardial damage not attributable to epicardial coronary artery disease or another cause (B)

## Diagnostic Investigations

### History and Physical Examination
As per JCS 2023 guidelines, Assess the following in patients with suspected myocarditis:

**History of Present Illness:**
- Time of onset and course of symptoms

**Past Medical History:**
- Skin rash (including insect bites)
- History of medication, vaccination, and ingestion of harmful materials
- Recent travel history
- History of autoimmune disease

**Physical Examination:**
- Fever and tachycardia (as signs of infection)
- Bradycardia or tachycardia (indicating arrhythmia)
- Low cardiac output (tachycardia, hypotension, cold extremities)
- Left-sided HF (hypoxemia, third or fourth heart sound, moist rales)
- Right-sided HF (jugular venous distention, hepatomegaly, peripheral edema) (B)

### ECG
As per JCS 2023 guidelines:
- Obtain a 12-lead ECG in all patients with suspected myocarditis based on signs and symptoms (B)
- Obtain periodic 12-lead ECGs and 24-hour ECG monitoring in patients diagnosed with acute myocarditis (B)

As per AHA 2016 guidelines, Obtain a 12-lead ECG in all patients with clinically suspected myocarditis (B)

As per ESC 2013 guidelines, Obtain standard 12-lead ECG in all patients with clinically suspected myocarditis (E)

### Transthoracic Echocardiography (TTE)
As per JCS 2023 guidelines:
- Obtain a TTE for the diagnosis of acute myocarditis (B)
- Monitor time-course changes in echocardiographic findings in acute myocarditis and assess fulminant changes and improvement of the pathological condition (B)

As per AHA 2016 guidelines, Obtain a standard TTE in all patients with clinically suspected myocarditis (B)

As per ESC 2013 guidelines:
- Obtain a standard TTE at presentation of patients with clinically suspected myocarditis (E)
- Repeat TTE during hospitalization in case of any worsening of hemodynamics (E)

### MRI
As per JCS 2023 guidelines, Obtain cardiac MRI for the diagnosis of myocarditis in patients with signs and symptoms suggestive of myocarditis and stable hemodynamics **(A)

As per CCS 2017 guidelines, Obtain cardiovascular MRI, where available and in the absence of contraindications, in all patients with HF and suspected myocarditis **(A)

As per AHA 2016 guidelines, Consider Obtaining cardiovascular MRI for diagnosis in clinically stable patients with clinically suspected myocarditis (C)

As per ESC 2013 guidelines:
- Use the Lake-Louise criteria for cardiovascular MRI diagnosis of myocarditis (E)
- Consider Obtaining cardiovascular magnetic resonance before endomyocardial biopsy in clinically stable patients. Recognize that cardiovascular magnetic resonance does not replace endomyocardial biopsy in the diagnosis of myocarditis and should not delay endomyocardial biopsy in life-threatening presentations (E)

### Lake Louise Criteria for Magnetic Resonance Imaging Diagnosis of Myocarditis

*Calculator Available*


### Nuclear Imaging
As per ESC 2013 guidelines, do not Obtain routine nuclear imaging in the diagnosis of myocarditis, with the possible exception of suspected cardiac sarcoidosis (D)

### Laboratory Tests

#### Inflammatory Markers
As per JCS 2023 guidelines, Obtain WBC count with differential and CRP in all patients with clinically suspected myocarditis (B); consider repeating these tests in patients diagnosed with myocarditis (B)

As per ESC 2013 guidelines, Obtain ESR and CRP level measurement in all patients with clinically suspected myocarditis (E)

#### Cardiac Biomarkers
As per JCS 2023 guidelines:
- Obtain CK-MB and cardiac troponin in all patients with clinically suspected myocarditis. Monitor serial changes of CK-MB and cardiac troponin in patients diagnosed with myocarditis (B)
- Obtain natriuretic peptide or NT-proBNP in patients with myocarditis possibly accompanied by HF (B)

As per AHA 2016 guidelines, Obtain cardiac troponin level measurement for diagnosis in patients with clinically suspected myocarditis (B)

As per ESC 2013 guidelines, Obtain troponin level measurement in all patients with clinically suspected myocarditis (E)

#### Metabolic Panel
As per JCS 2023 guidelines, Obtain liver and renal function tests, electrolytes, and lactate in patients with myocarditis possibly accompanied by HF (B)

#### Serology
As per JCS 2023 guidelines:
- Obtain relevant autoantibodies in patients with myocarditis possibly accompanied by autoimmune disease (B)
- Do not Obtain routine viral serological tests to identify the causal virus in patients with myocarditis (D)

As per ESC 2013 guidelines:
- Obtain cardiac autoantibodies (preferably disease-specific), if possible and available, according to specific center expertise (E)
- Do not Obtain routine viral serology testing in patients with clinically suspected myocarditis (D)

## Diagnostic Procedures

### Coronary Angiography
As per ESC 2013 guidelines, Consider Obtaining selective coronary angiography in all patients with clinically suspected myocarditis (E)

### Endomyocardial Biopsy
As per JCS 2023 guidelines, Perform an endomyocardial biopsy, if available, in patients with suspected acute myocarditis accompanied by acute HF, severe HF, cardiogenic shock, ventricular arrhythmias, or advanced AV block (B)

As per CCS 2017 guidelines, Consider performing an endomyocardial biopsy in patients with HF presenting with any of the following characteristics:
- New-onset (< 2 weeks) of undetermined etiology with hemodynamic compromise
- High-grade heart block
- Recurrent ventricular arrhythmias
- Unresponsive to medical therapy (C)

As per AHA 2016 guidelines, Perform an endomyocardial biopsy in patients with clinically suspected, unexplained acute myocarditis requiring inotropic support or mechanical circulatory support and in patients with Mobitz type 2 second-degree or higher heart block, sustained or symptomatic VT, or failure to respond to guideline-based medical management within 1-2 weeks (B)

As per AHA 2016 guidelines, Consider performing an endomyocardial biopsy in patients with suspected eosinophilic myocarditis (C)

As per ESC 2013 guidelines, Consider performing an endomyocardial biopsy in all patients with clinically suspected myocarditis (E)

## Medical Management

### Setting of Care
As per JCS 2023 guidelines, Consider hospitalizing patients with acute myocarditis and Obtaining monitoring for at least 48 hours, even with stable hemodynamics or no HF symptoms (C)

As per ESC 2022 guidelines, Refer patients with confirmed or clinically suspected acute myocarditis presenting with life-threatening ventricular arrhythmias to a specialized center (B)

As per ACC/AHA/HRS 2018 guidelines, Refer patients with life-threatening VT or VF associated with confirmed or clinically suspected myocarditis to centers with mechanical hemodynamic support and advanced arrhythmia management (B)

As per CCS 2017 guidelines:
- Consider referring patients with suspected myocarditis to a center with experience and expertise in the assessment and management of myocarditis (B)
- Consider referring patients with myocarditis associated with HF, progressive clinical deterioration, or end-organ dysfunction despite standard HF therapy urgently for evaluation/consideration for cardiac transplantation or mechanical circulatory support (B)

As per ESC 2013 guidelines, Refer patients with a life-threatening presentation to specialized units with capability for hemodynamic monitoring, cardiac catheterization, and expertise in endomyocardial biopsy (E)

### Management of Fulminant Myocarditis

#### Inotropic Support
As per JCS 2023 guidelines:
- Consider administering dobutamine or a PDE3 inhibitor for pump failure and pulmonary congestion (C)
- Consider administering norepinephrine (C)e in patients with cardiogenic shock (C)(C)

#### Circulatory Support
As per JCS 2023 guidelines, Perform venoarterial ECMO in patients with cardiogenic shock or lethal arrhythmia (B)

### Management of Heart Failure
As per JCS 2023 guidelines:
- Consider initiating guideline-directed medical therapy for HFrEF in patients with reduced LVEF (< 50%) early after onset (C)
- Consider initiating guideline-directed medical therapy for HFrEF in patients with adequate LVEF (≥ 50%) (C)

As per AHA 2016 guidelines, Manage patients with HF caused by clinically suspected or confirmed myocarditis according to the current HF guidelines (B)

As per ESC 2013 guidelines:
- Manage ventricular dysfunction in line with current guidelines on HF (E)
- Consider performing placement of mechanical cardiopulmonary assist device as a bridge to recovery or to heart transplantation in patients with hemodynamic instability (E)

### Management of Cardiac Arrhythmias

#### General Principles
As per ESC 2013 guidelines, Manage arrhythmia outside the acute phase of myocarditis in line with current guidelines on arrhythmia and device implantation (E)

#### Antiarrhythmic Drugs
As per ESC 2022 guidelines:
- Consider initiating antiarrhythmic drugs, preferably amiodarone and β-blockers, in patients with symptomatic non-sustained or sustained ventricular arrhythmias during the acute phase of myocarditis (C)
- Consider initiating antiarrhythmic drugs in post-myocarditis patients with recurrent, symptomatic VT (C)

#### Sedation
As per JCS 2023 guidelines, Consider administering sedation to suppress sympathetic activity in an electrical storm (C)

#### Cardiac Pacing
As per JCS 2023 guidelines, Perform temporary pacing in patients with unstable hemodynamics due to bradyarrhythmia (B)

#### ICD Implantation
As per JCS 2023 guidelines:
- Decide on the indication of an implantable device (implantable cardioverter defibrillator, CRT defibrillator) for sudden death prevention 3-6 months after the acute phase or later, based on the clinical course and the pathological assessment (B)
- Consider placing a wearable cardioverter defibrillator to prevent sudden death in patients with a high risk of SCD or complicating ventricular arrhythmia in the acute phase (C)

As per ESC 2022 guidelines:
- Consider performing ICD placement before hospital discharge in patients with hemodynamically not-tolerated sustained VT or VF during the acute phase of myocarditis (C)
- Consider performing ICD placement in patients with hemodynamically tolerated sustained monomorphic VT occurring in the chronic phase of myocarditis (C)

As per AHA 2016 guidelines, Do not perform ICD placement in patients with recent-onset dilated cardiomyopathy and LVEF < 30% caused by clinically suspected or confirmed myocarditis in the absence of ventricular arrhythmias or syncope (D)

As per ESC 2013 guidelines, Defer ICD implantation until resolution of the acute episode (E)

#### ECMO
As per JCS 2023 guidelines, Perform venoarterial ECMO in patients with lethal arrhythmia (particularly electrical storm) (B)

#### Catheter Ablation
As per ESC 2022 guidelines:
- Consider performing catheter ablation in specialized centers in post-myocarditis patients with recurrent, symptomatic sustained monomorphic VT or ICD shocks for sustained monomorphic VT, if antiarrhythmic drugs are ineffective, not tolerated, or not desired (C)
- Consider performing catheter ablation as an alternative to ICD therapy, after discussion with the patient and provided that established endpoints have been reached, in patients with hemodynamically well-tolerated sustained monomorphic VT occurring in the chronic phase of myocarditis, preserved LV function, and a limited scar amenable to ablation (C)

### Immunosuppressive Therapy
As per JCS 2023 guidelines, Do not initiate routine immunosuppressive therapy in patients with acute lymphocytic myocarditis (D)

As per CCS 2017 guidelines:
- Do not use general or specific immunological therapies directed toward myocarditis (D)
- Consider initiating immunosuppressive therapy in subgroups of patients with myocarditis due to specific underlying etiologies, such as giant cell myocarditis, sarcoidosis, myocarditis due to systemic autoimmune disease, or biopsy-proven myocarditis with undetectable viral infection using PCR (C)

As per AHA 2016 guidelines:
- Initiate immunosuppressive therapy including calcineurin inhibitors and corticosteroids for the treatment of acute dilated cardiomyopathy caused by giant cell myocarditis (B)
- Consider initiating IV corticosteroids, systemic immunosuppressants, or immunomodulatory agents in patients with biopsy-proven myocarditis believed to be caused by SLE, rheumatoid arthritis, or polyarteritis nodosa (C)

As per ESC 2013 guidelines, Consider initiating immunosuppressive therapy, if not contraindicated, in patients with proven autoimmune (infection-negative) forms of myocarditis, including giant cell myocarditis, cardiac sarcoidosis, and myocarditis associated with known extra-cardiac autoimmune disease (E)

### Antiviral Therapy
As per CCS 2017 guidelines, Do not use antiviral therapy routinely in patients with myocarditis (D)

## Nonpharmacologic Interventions

### Physical Activity Restrictions
As per JCS 2023 guidelines, Consider advising refraining from intense exercise for 6 months after onset in patients with improved HF symptoms, cardiac enzymes, abnormal ECG, and image findings (C)

As per AHA 2016 guidelines, Advise refraining from competitive sports for a minimum of 3-6 months in patients with HF caused by clinically suspected or confirmed myocarditis (B)

As per ACC/AHA 2015 guidelines, Advise refraining from participation in competitive sports in athletes with probable or definite myocarditis while active inflammation is present (B)

As per ESC 2013 guidelines, Advise restriction of physical activity during the acute phase of myocarditis and for at least 6 months in athletes and non-athletes (E)

## Surgical Interventions

### Heart Transplantation
As per ESC 2013 guidelines:
- Defer cardiac transplantation in the acute phase of myocarditis as recovery may occur (E)
- Consider performing cardiac transplantation in the acute phase of myocarditis in hemodynamically unstable patients, including with giant cell myocarditis, when optimal pharmacological support and mechanical assistance failed to stabilize the patient (E)

## Specific Circumstances

### Neonatal Patients

#### Evaluation
As per JCS 2023 guidelines, Obtain an ECG and echocardiography to diagnose myocarditis in neonatal patients (B)

#### Management
As per JCS 2023 guidelines:
- Consider initiating immunoglobulin and immunosuppressive therapy in neonatal patients with myocarditis (C)
- Perform venoarterial ECMO in neonatal patients with fulminant myocarditis (B)

### Pediatric Patients

#### Evaluation
As per JCS 2023 guidelines, Obtain cardiac enzymes, cardiac troponins, echocardiography, and cardiac MRI to diagnose myocarditis in pediatric patients (B)

As per AHA 2016 guidelines:
- Consider Obtaining nasal swabs and stool specimens to evaluate for viruses as well as blood PCR in patients with suspected myocarditis (C)
- Consider performing an endomyocardial biopsy to guide further therapy in young patients with clinical signs of myocarditis failing to recover (C)

#### Immunosuppressive Therapy
As per JCS 2023 guidelines:
- Consider administering immunoglobulin therapy in pediatric patients with acute myocarditis (C)
- Consider initiating immunosuppressive therapy in pediatric patients with acute myocarditis (C)

As per AHA 2016 guidelines:
- Consider administering IVIG in young patients with clinical or biopsy-proven myocarditis (C)
- Do not use corticosteroids in pediatric patients with clinical signs of myocarditis (D)

#### Advanced Cardiac Life Support
As per JCS 2023 guidelines, Initiate mechanical circulatory support in pediatric patients with fulminant myocarditis associated with cardiogenic shock or life-threatening arrhythmias (B)

As per AHA 2020 guidelines, Consider referring pediatric patients with acute myocarditis presenting with arrhythmias, heart block, ST-segment changes, and/or low cardiac output early to ICU monitoring and therapy, given the high risk of cardiac arrest (B)

#### Patients with Vasculitides
As per SHARE initiative 2019 guidelines, Consider Obtaining an ECG and echocardiography to assess for myocarditis in patients with polyarteritis nodosa (C)

### Patients with Myopericarditis
As per EACTS/ESC 2015 guidelines, Obtain coronary angiography (according to clinical presentation and risk factor assessment) to rule out ACSs in patients with pericarditis and suspected myocarditis (B)

### Patients with Giant Cell Myocarditis

#### Immunosuppressive Therapy
As per JCS 2023 guidelines, Initiate combination immunosuppressive therapy in the early stages (B)

As per CCS 2017 guidelines, Consider initiating immunosuppressive therapy in patients with giant cell myocarditis (C)

As per AHA 2016 guidelines, Initiate immunosuppressive therapy including calcineurin inhibitors and corticosteroids for the treatment of acute dilated cardiomyopathy caused by giant cell myocarditis (B)

As per ESC 2013 guidelines, Consider initiating immunosuppressive therapy in patients with giant cell myocarditis, unless contraindicated (E)

#### Management of Cardiac Arrhythmia
As per JCS 2023 guidelines, Place an ICD in patients with a history of cardiac arrest or sustained VT (B)

As per ACC/AHA/HRS 2018 guidelines, Consider placing an ICD and/or initiating antiarrhythmic medications in patients with giant cell myocarditis with VF or hemodynamically unstable VT treated according to guideline-directed medical therapy, if the expected meaningful survival is > 1 year (C)

#### Heart Transplantation
As per ESC 2013 guidelines, Consider performing cardiac transplantation in the acute phase of myocarditis in hemodynamically unstable patients with giant cell myocarditis when optimal pharmacological support and mechanical assistance failed to stabilize the patient (E)

### Patients with Eosinophilic Myocarditis
As per JCS 2023 guidelines, Consider performing an endomyocardial biopsy in patients with suspected acute myocarditis accompanied by peripheral eosinophilia (C)

### Patients with Immune Checkpoint Inhibitor-Induced Myocarditis

#### Evaluation
As per EHA/ESC/ESTRO/IC-OS 2022 guidelines, Obtain cardiac troponin, ECG, and cardiovascular imaging (echocardiography and cardiac MRI) to diagnose immune checkpoint inhibitor-associated myocarditis (B)

As per ESMO 2020 guidelines:
- Obtain appropriate work-up (ECG, troponin, BNP or NT-proBNP, CRP, viral titer, echocardiogram with global longitudinal strain, cardiac MRI) for immune checkpoint inhibitor-associated cardiovascular toxicity, particularly myocarditis and other common differential diagnoses, in patients developing new cardiovascular symptoms or with incidentally detected arrhythmia, conduction abnormality on ECG, or LV systolic dysfunction on echocardiogram, while undergoing (or after recent completion) of immune checkpoint inhibitor therapy (B)
- Consider performing an endomyocardial biopsy for diagnostic confirmation if the diagnosis is highly suspected with otherwise negative work-up (C)

#### Management
As per EHA/ESC/ESTRO/IC-OS 2022 guidelines, Interrupt immune checkpoint inhibitor treatment in patients with confirmed immune checkpoint inhibitor-associated myocarditis (B)

As per ESMO 2020 guidelines, Withhold further therapy with immune checkpoint inhibitors and initiate high-dose corticosteroids (methylprednisolone 1,000 mg/day, followed by oral prednisone 1 mg/kg/day) promptly in patients with either suspected or confirmed immune checkpoint inhibitor-associated myocarditis. Continue corticosteroids until resolution of symptoms and normalization of troponin, LV systolic function, and conduction abnormalities (B)

#### Restarting ICI Therapy
As per EHA/ESC/ESTRO/IC-OS 2022 guidelines, Arrange a multidisciplinary discussion before restarting immune checkpoint inhibitor treatment in selected patients with previous uncomplicated immune checkpoint inhibitor-associated myocarditis (B)

As per ESMO 2020 guidelines, Individualize the decision on restarting immune checkpoint inhibitor therapy in the absence of alternative available antineoplastic therapies with multidisciplinary discussion considering the cancer status, response to prior therapy, the severity of cardiotoxicity, regression of toxicity with immunosuppressive therapy, and patient preference after weighing the risks and benefits. Consider offering monotherapy with an anti-PD-L1 agent with very close surveillance for cardiotoxicity development if immune checkpoint inhibitor therapy needs to be restarted (B)

## Follow-up and Surveillance

### Clinical and Imaging Follow-up
As per ESC 2023 guidelines, Consider Obtaining contrast-enhanced cardiac MRI in the serial follow-up and for the assessment of therapeutic response in patients with inflammatory cardiomyopathy (C)

As per JCS 2023 guidelines, Consider Obtaining long-term regular check-ups, including ECG and cardiac ultrasound, after the resolution of symptoms (C)

As per CCS 2017 guidelines, Obtain clinical follow-up until resolution of myocarditis or until a chronic management plan is in place (B)

As per ESC 2013 guidelines:
- Obtain monitoring with clinical assessment, ECG, and echocardiography in all patients with myocarditis (E)
- Obtain long-term follow-up in patients after myocarditis (E)

### Endomyocardial Biopsy Follow-up
As per ESC 2013 guidelines, Consider performing a follow-up endomyocardial biopsy to guide the intensity and the length of immunosuppression (E)

### Return to Sport Activities
As per ACC/AHA 2015 guidelines:
- Obtain a resting echocardiogram, 24-hour Holter monitoring, and an exercise ECG ≥ 3-6 months after the initial illness before returning to competitive sports in athletes initially presented with an acute clinical syndrome consistent with myocarditis (B)
- Consider advising athletes to resume training and competition if all of the following criteria are met:
  - Ventricular systolic function has returned to the normal range
  - Serum markers of myocardial injury, inflammation, and HF have normalized
  - Clinically relevant arrhythmias, such as frequent or complex repetitive forms of ventricular or supraventricular ectopic activity, are absent on Holter monitoring and graded exercise ECGs (C)

## References

1. Justin A Ezekowitz, Eileen O'Meara, Michael A McDonald et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. 2017 Nov;33(11):1342-1433. [Open](https://pubmed.ncbi.nlm.nih.gov/29111106/)

2. Biykem Bozkurt, Monica Colvin, Jennifer Cook et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. Circulation. 2016 Dec 6;134(23):e579-e646. [Open](https://pubmed.ncbi.nlm.nih.gov/27832612/)

3. Toshiyuki Nagai, Takayuki Inomata, Takashi Kohno et al. JCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis. Circ J. 2023 Mar 10. [Open](https://pubmed.ncbi.nlm.nih.gov/36889897/)

4. Alexander R Lyon, Teresa López-Fernández, Liam S Couch et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022 Sep 10;23(10):e333-e465. [Open](https://pubmed.ncbi.nlm.nih.gov/36017572/)

5. Alida L P Caforio, Sabine Pankuweit, Eloisa Arbustini et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d. [Open](https://pubmed.ncbi.nlm.nih.gov/23824828/)

6. G Curigliano, D Lenihan, M Fradley et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020 Feb;31(2):171-190. [Open](https://pubmed.ncbi.nlm.nih.gov/31959341/)

7. Katja Zeppenfeld, Jacob Tfelt-Hansen, Marta de Riva et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997-4126. [Open](https://pubmed.ncbi.nlm.nih.gov/36017572/)

8. Barry J Maron, James E Udelson, Robert O Bonow et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2015 Dec 1;132(22):e273-80. [Open](https://pubmed.ncbi.nlm.nih.gov/26621644/)

9. Nienke de Graeff, Noortje Groot, Paul Brogan et al. European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides - the SHARE initiative. Rheumatology (Oxford). 2019 Apr 1;58(4):656-671. [Open](https://pubmed.ncbi.nlm.nih.gov/30329113/)

10. Alexis A Topjian, Tia T Raymond, Dianne Atkins et al. Part 4: Pediatric Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020 Oct 20;142(16_suppl_2):S469-S523. [Open](https://pubmed.ncbi.nlm.nih.gov/33081529/)

11. Adler Y, Charron P, Imazio M et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015 Nov 7;36(42):2921-2964. [Open](https://pubmed.ncbi.nlm.nih.gov/26320112/)

12. Sana M Al-Khatib, William G Stevenson, Michael J Ackerman et al. 2017 AHA / ACC / HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 Sep 25;138(13):e272-e391. [Open](https://pubmed.ncbi.nlm.nih.gov/30354651/)

13. Elena Arbelo, Alexandros Protonotarios, Juan R Gimeno et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-3626. [Open](https://pubmed.ncbi.nlm.nih.gov/37622657/)

14. Matthias G Friedrich, Udo Sechtem, Jeanette Schulz-Menger et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009 Apr 28;53(17):1475-87. [Open](https://pubmed.ncbi.nlm.nih.gov/19389557/)

15. Robb D Kociol, Leslie T Cooper, James C Fang et al. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association. Circulation. 2020 Feb 11;141(6):e69-e92. [Open](https://pubmed.ncbi.nlm.nih.gov/31992059/)

16. Tun-Chieh Chen, Po-Laing Lu, Chun-Yu Lin et al. Escherichia coli urosepsis complicated with myocarditis mimicking acute myocardial infarction. Am J Med Sci. 2010 Oct;340(4):332-4. [Open](https://pubmed.ncbi.nlm.nih.gov/20881759/)

17. Mitra Esfandiarei, Bruce M McManus. Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol. 2008:3:127-55. [Open](https://pubmed.ncbi.nlm.nih.gov/18039136/)

18. Sandeep Sagar, Peter P Liu, Leslie T Cooper Jr. Myocarditis. Lancet. 2012 Feb 25;379(9817):738-47. [Open](https://pubmed.ncbi.nlm.nih.gov/22185868/)

19. Lei Lu, RongRong Sun, Min Liu et al. The Inflammatory Heart Diseases: Causes, Symptoms, and Treatments. Cell Biochem Biophys. 2015 Jul;72(3):851-5. [Open](https://pubmed.ncbi.nlm.nih.gov/25708350/)

20. Ainoosh Golpour, Dimitri Patriki, Paul J Hanson et al. Epidemiological Impact of Myocarditis. J Clin Med. 2021 Feb 5;10(4):603. [Open](https://pubmed.ncbi.nlm.nih.gov/33562715/)

